Research graph
References from High rates of transition to immune active disease in a cohort of strictly defined immune tolerant patients with chronic hepatitis B: results from the RADICAL consortium. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
10.1016/j.jhep.2025.03.018 · 2025 · External reference
10.1002/hep.29800
10.1002/hep.29800 · External reference
10.1053/j.gastro.2016.07.012
10.1053/j.gastro.2016.07.012 · External reference
Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B
10.1016/j.ejim.2020.10.022 · 2021 · External reference
10.1136/gutjnl-2017-314904
10.1136/gutjnl-2017-314904 · External reference
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients
10.1111/apt.15725 · 2020 · External reference
AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis
10.1097/hep.0000000000000845 · 2025 · External reference
10.1002/sim.2712
10.1002/sim.2712 · External reference
10.18637/jss.v038.i07
10.18637/jss.v038.i07 · External reference
10.2307/2670170
10.2307/2670170 · External reference
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
10.3350/cmh.2020.0216 · 2021 · External reference
Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase
10.1002/hep.21724 · 2007 · External reference
Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B
10.1016/j.cgh.2025.04.024 · 2026 · External reference
Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection
10.1016/j.cgh.2022.06.015 · 2023 · External reference
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase
10.1111/apt.15741 · 2020 · External reference
10.1002/hep.23803
10.1002/hep.23803 · External reference
10.1053/j.gastro.2014.01.044
10.1053/j.gastro.2014.01.044 · External reference
10.1053/j.gastro.2021.12.286
10.1053/j.gastro.2021.12.286 · External reference
10.1136/gutjnl-2025-335449
10.1136/gutjnl-2025-335449 · External reference
Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase
10.1002/hep.21724 · ExternalCitation · doi-reference
10.1002/hep.23803
10.1002/hep.23803 · ExternalCitation · doi-reference
10.1002/hep.29800
10.1002/hep.29800 · ExternalCitation · doi-reference
10.1002/sim.2712
10.1002/sim.2712 · ExternalCitation · doi-reference
Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection
10.1016/j.cgh.2022.06.015 · ExternalCitation · doi-reference
Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B
10.1016/j.cgh.2025.04.024 · ExternalCitation · doi-reference
Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B
10.1016/j.ejim.2020.10.022 · ExternalCitation · doi-reference
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
10.1016/j.jhep.2025.03.018 · ExternalCitation · doi-reference
10.1053/j.gastro.2014.01.044
10.1053/j.gastro.2014.01.044 · ExternalCitation · doi-reference
10.1053/j.gastro.2016.07.012
10.1053/j.gastro.2016.07.012 · ExternalCitation · doi-reference
10.1053/j.gastro.2021.12.286
10.1053/j.gastro.2021.12.286 · ExternalCitation · doi-reference
AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis
10.1097/hep.0000000000000845 · ExternalCitation · doi-reference
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients
10.1111/apt.15725 · ExternalCitation · doi-reference
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase
10.1111/apt.15741 · ExternalCitation · doi-reference
10.1136/gutjnl-2017-314904
10.1136/gutjnl-2017-314904 · ExternalCitation · doi-reference
10.1136/gutjnl-2025-335449
10.1136/gutjnl-2025-335449 · ExternalCitation · doi-reference
10.18637/jss.v038.i07
10.18637/jss.v038.i07 · ExternalCitation · doi-reference
10.2307/2670170
10.2307/2670170 · ExternalCitation · doi-reference
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
10.3350/cmh.2020.0216 · ExternalCitation · doi-reference
